Fewer than 10% of patients eligible to benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it releases its initial advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to these injectable treatments.
Based on estimates, more than two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a long-term condition that can be addressed with comprehensive and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to broad access to the injections that can aid individuals in losing substantial weight, says the agency.
Weight-Loss Drug Supply Crisis
Even in the current best projected outlook, the supply of these medications would only suffice for approximately 100 million people – under 10% of those who need them, per the WHO.
The advice encourages nations and manufacturers to expand availability, by approaches such as patent sharing.
A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs mimick a biological compound to slow digestion, suppress the appetite and increase feelings of fullness so people eat less.
People commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Evidence suggests people may see weight return after a year of halting the treatment, as their usual food cravings resume.
To be carrying excess weight increases your likelihood for contracting diseases, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
